Cargando…

Study protocol for a randomised, double-blind, placebo-controlled crossover trial assessing the impact of the SGLT2 inhibitor empagliflozin on postprandial hypoglycaemia after gastric bypass

INTRODUCTION: Postprandial hypoglycaemia after gastric bypass surgery (also known as postbariatric hypoglycaemia or PBH) is an increasingly encountered clinical problem. PBH is characterised by meal-induced rapid spikes and consequent falls in glycaemia, resulting in both hypoglycaemia burden and hi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferreira, Antonio, Emara, Ahmed Fahiem Abdelsalam, Herzig, David, Melmer, Andreas, Vogt, Andreas P, Nakas, Christos T, Facchinetti, Andrea, Dalla Man, Chiara, Bally, Lia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Diabetes and Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486284/ https://www.ncbi.nlm.nih.gov/pubmed/36123073 http://dx.doi.org/10.1136/bmjopen-2021-060668

Ejemplares similares

Counter-regulatory responses to postprandial hypoglycaemia in patients with post-bariatric hypoglycaemia vs surgical and non-surgical control individuals
por: Tripyla, Afroditi, et al.
Publicado: (2023)

Forecasting postbariatric hypoglycaemia in patients after Roux‐en‐Y gastric bypass using model‐based algorithms fed by continuous glucose monitoring data: A proof‐of‐concept study
por: Prendin, Francesco, et al.
Publicado: (2022)

Model-Based Assessment of C-Peptide Secretion and Kinetics in Post Gastric Bypass Individuals Experiencing Postprandial Hyperinsulinemic Hypoglycemia
por: Schiavon, Michele, et al.
Publicado: (2021)

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on β-Cell Function at 1 Year After Surgery: A Systematic Review
por: Buser, Angeline, et al.
Publicado: (2022)

Postprandial Glucose and Triglyceride Increases Along with the Endothelial Malfunction were Attenuated by the Administration of SGLT2 Inhibitor, Empagliflozin
por: Masuda, Daisaku, et al.
Publicado: (2020)

The Hypoglycaemia-Hyperglycaemia Minimizer System in the Management of Type 1 Diabetes
por: Levy, Brian L, et al.
Publicado: (2016)

Impact of the SGLT2 inhibitor empagliflozin on urinary supersaturations in kidney stone formers (SWEETSTONE trial): protocol for a randomised, double-blind, placebo-controlled cross-over trial
por: Schietzel, Simeon, et al.
Publicado: (2022)

A Rare but Life-Threatening Case of Fournier’s Gangrene Caused by Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor, Empagliflozin
por: Jahir, Tahmina, et al.
Publicado: (2022)

Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes
por: Rajendran, Rajesh, et al.
Publicado: (2014)

Roux-en-Y Gastric Bypass Surgery Leading to Postprandial Hypoglycemia: A Case Report
por: Coelho, Telmo, et al.
Publicado: (2022)

Hypoglycaemia Unawareness: Causes, Consequences and Treatment
por: MacLeod, Kenneth M
Publicado: (2000)

Hypoglycaemia in a Patient Taking Tetracyclines
por: Fahad, Muhammad, et al.
Publicado: (2023)

Empagliflozin and Cardio-renal Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease – Implications for Clinical Practice
por: Fitchett, David H
Publicado: (2018)

A novel technique of Roux-en-Y gastric bypass reversal for postprandial hyperinsulinemic hypoglycaemia: A case report
por: Qvigstad, E., et al.
Publicado: (2016)

The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
por: Steven, Sebastian, et al.
Publicado: (2017)

Empagliflozin-Associated Pancreatitis: A Consideration for SGLT2 Inhibitors
por: Dziadkowiec, Karolina N., et al.
Publicado: (2021)

Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy
por: Gallwitz, Baptist
Publicado: (2016)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

OR27-6 Effects of the SGLT2-Inhibitor Empagliflozin in Patients With Chronic Syndrome of Inadequate Antidiuresis (SIAD) - Results of a Double-Blind, Randomized, Placebo-Controlled, Crossover Trial
por: Berres, Manfred, et al.
Publicado: (2022)

Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME(®) trial
por: Fitchett, David, et al.
Publicado: (2020)

LBSUN290 A Rare, Sordid Tale Of The Two Most Dreaded Adverse Effects Of SGLT-2 Inhibitors Occurring Concurrently - Acute Pancreatitis And Euglycemic Diabetic Ketoacidosis - Within Days Of Initiating Empagliflozin Therapy.
por: Arora, Gunjan, et al.
Publicado: (2022)

Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy
por: Matthews, Jennifer, et al.
Publicado: (2022)

Hypoglycaemia Awareness Restoration Programme for People with Type 1 Diabetes and Problematic Hypoglycaemia Persisting Despite Optimised Self-care (HARPdoc): protocol for a group randomised controlled trial of a novel intervention addressing cognitions
por: Amiel, Stephanie A, et al.
Publicado: (2019)

RF16 | PSUN155 Empagliflozin and the risk of nephrolithiasis
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Empagliflozin, calcium, and SGLT1/2 receptor affinity: another piece of the puzzle
por: Anker, Stefan D., et al.
Publicado: (2018)

Empagliflozin and Protecting Microvascular Support of Heart Mechanics: SGLT2 Inhibition or More?
por: Mantsounga, Chris Sorel, et al.
Publicado: (2019)

SGLT2 Inhibitor Empagliflozin Modulates Ion Channels in Adult Zebrafish Heart
por: Karpushev, Alexey V., et al.
Publicado: (2022)

Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
por: Heimke, Marvin, et al.
Publicado: (2022)

THU371 Empagliflozin Associated Pancreatitis: A Case Report
por: Poloju, Alekya, et al.
Publicado: (2023)

Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice
por: Pennig, Jan, et al.
Publicado: (2019)

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes
por: Sands, Arthur T., et al.
Publicado: (2015)

ODP249 The Effects of Rice From Starch-removing Rice Cooker on Postprandial Glucose And Insulin Levels in Healthy Adults: A Randomized, Double-blind, Crossover Study
por: Bhekasuta, Apanaree, et al.
Publicado: (2022)

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)
por: Jürgens, Mikkel, et al.
Publicado: (2019)

Factors associated with fear of hypoglycaemia among the T1D Exchange Glu population in a cross-sectional online survey
por: Liu, Jingwen, et al.
Publicado: (2020)

Adverse Side Effects: Empagliflozin-Related Acute Pancreatitis Case Report
por: Zeidan, Bassem S, et al.
Publicado: (2020)

ODP192 Empagliflozin associated Euglycemic Diabetic Ketoacidosis and the Terrible Triad
por: Nievera, Karl Homer, et al.
Publicado: (2022)

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?
por: Balasubramanian, Priyadarshini, et al.
Publicado: (2022)

Baseline neutrophil‐to‐lymphocyte ratio and efficacy of SGLT2 inhibition with empagliflozin on cardiac remodelling
por: Verma, Raj, et al.
Publicado: (2023)

Investigating the day-to-day impact of hypoglycaemia in adults with type 1 or type 2 diabetes: design and validation protocol of the Hypo-METRICS application
por: Søholm, Uffe, et al.
Publicado: (2022)

A Rare Case of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis Obscured by Alkalosis
por: Fernandez Felix, Daniel A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vk60gl5gak8jj09ke7harpq8u8